Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US



Status:Completed
Conditions:Vaccines, Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:7/14/2018
Start Date:January 1, 2009
End Date:August 2, 2012

Use our guide to learn which trials are right for you!

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008

This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV
vaccine GSK580299 in female subjects who took part in study 580299/008 and received the
control vaccine (Hepatitis A vaccine).


Inclusion Criteria:

- Subjects who the investigator believes that they can and will comply with the
requirements of the protocol should be enrolled in the study

- A subject previously enrolled in the primary study (NCT00122681), who received the
active control hepatitis A vaccine, and who cannot receive commercially available
HPV-16/18 L1 VLP AS04 vaccine because the vaccine has not yet been granted licensure
in the subject's country or because the subject is above the age for which the vaccine
is licensed.

- Written informed consent must be obtained from the subject prior to enrolment.

- A woman aged 18 years or older, at the time of the first vaccination in this study.

- Healthy subjects as established by medical history and clinical examination before
entering into the study.

- Subjects must not be pregnant. Absence of pregnancy should be verified with a urine
pregnancy test.

- Subject must be of non-childbearing potential, or if she is of childbearing potential,
she must practice adequate contraception for 30 days prior to vaccination, have a
negative pregnancy test and continue such precautions for 2 months after completion of
the vaccination series.

Exclusion Criteria:

- Pregnant or lactating female. Enrolment should be deferred until three months after
pregnancy has been completed or after lactating has ceased.

- A woman planning to become pregnant or likely to become pregnant (as determined by the
investigator) or planning to discontinue contraceptive prevention during the study
period and up to two months after the last vaccine dose.

- Use of any investigational or non-registered product (drug or vaccine) other than the
study vaccine within 30 days preceding the first dose of study vaccine, or planned use
during the study period and the extended safety follow-up period.

- Concurrently participating in another clinical study at any time during the study
period, in which the subject has been or will be exposed to an investigational or
non-investigational product (pharmaceutical product or device).

- Previous vaccination against HPV or planned administration of another HPV vaccine
during the study other than that foreseen by protocol.

- Planned administration/ administration of a vaccine not foreseen by the study protocol
within 30 days (i.e. Day 0-29) of each dose of vaccine. Administration of routine
meningococcal, hepatitis B, hepatitis A, inactivated influenza, diphtheria/tetanus
and/or diphtheria/tetanus-containing vaccine up to 8 days before each dose of study
vaccine is allowed. Enrolment will be deferred until the subject is outside of
specified window.

- Previous administration of components of the investigational vaccine.

- History of allergic disease, suspected allergy or reactions likely to be exacerbated
by any component of the study vaccine.

- Hypersensitivity to latex.

- Acute or chronic, clinically significant pulmonary, cardiovascular, neurologic,
haematological, hepatic or renal functional abnormality, as determined by previous
physical examination or laboratory tests, which in the opinion of the investigator
precludes administration of the study vaccine.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination.

- Cancer or autoimmune disease under treatment.

- Chronic administration (defined as more than 14 days) of immunosuppressants or other
immune-modifying drugs within six months prior to the first vaccine dose.

- Acute disease at the time of enrolment.
We found this trial at
38
sites
Webster, Texas 77450
?
mi
from
Webster, TX
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Arkansas City, Kansas 67005
?
mi
from
Arkansas City, KS
Click here to add this to my saved trials
Augusta, Georgia 30909
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bardstown, Kentucky 40004
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Carnegie, Pennsylvania 15106
?
mi
from
Carnegie, PA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlottesville, Virginia 22903
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Clearwater, Florida 33759
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
Cleveland, Ohio 44195
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Denver, Colorado 80206
?
mi
from
Denver, CO
Click here to add this to my saved trials
Edmonton, Alberta
?
mi
from
Edmonton,
Click here to add this to my saved trials
Erie, Pennsylvania 16507
?
mi
from
Erie, PA
Click here to add this to my saved trials
Honolulu, Hawaii 96813
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Louisville, Colorado 80027
?
mi
from
Louisville, CO
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Morristown, New Jersey 07962
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
New Bern, North Carolina 28562
?
mi
from
New Bern, NC
Click here to add this to my saved trials
New York, New York 10032
?
mi
from
New York, NY
Click here to add this to my saved trials
Newton, Kansas 67114
?
mi
from
Newton, KS
Click here to add this to my saved trials
Omaha, Nebraska 68131
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pleasant Hills, Pennsylvania 15236
?
mi
from
Pleasant Hills, PA
Click here to add this to my saved trials
Portland, Oregon 97227
?
mi
from
Portland, OR
Click here to add this to my saved trials
Poughkeepsie, New York 12601
?
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
San Diego, California 92111
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Francisco, California 94115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Spokane, Washington 99208
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Tulsa, Oklahoma 74105
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Wenatchee, Washington 98801
?
mi
from
Wenatchee, WA
Click here to add this to my saved trials
West Palm Beach, Florida 33409
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Wichita, Kansas 67207
?
mi
from
Wichita, KS
Click here to add this to my saved trials